The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.
 
Gerard Zalcman
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Da Volterra; Inventiva Pharma; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Da Volterra (Inst); Inventiva Pharma (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche (Inst); ROCHE (Inst); ROCHE (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer; Pfizer; Roche
 
Anne Madroszyk
No Relationships to Disclose
 
Charles Dayen
No Relationships to Disclose
 
Olivier Molinier
No Relationships to Disclose
 
Thomas Egenod
No Relationships to Disclose
 
Didier Debieuvre
Honoraria - AstraZeneca; BMS France; GlaxoSmithKline; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; BMS France; Ipsen; Janssen; MSD Oncology; Novartis; OSE Immunotherapeutics; Pfizer; Sanofi/Aventis
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS france (Inst); Boehringer Ingelheim (Inst); Chiesi (Inst); Chugai Pharma (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS France; BMS france; BMS france; Boehringer Ingelheim; Boehringer Ingelheim France; Lilly (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; novartis France; Pfizer; Roche; Roche; Takeda
 
Sophie Beaucaire-Danel
No Relationships to Disclose
 
Adrien Dixmier
No Relationships to Disclose
 
Eric Pichon
No Relationships to Disclose
 
Sigolène Galland-Girodet
No Relationships to Disclose
 
Etienne Giroux Leprieur
No Relationships to Disclose
 
Nicolas Cloarec
Travel, Accommodations, Expenses - Takeda
 
Jacques Cadranel
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme
Consulting or Advisory Role - Abbvie (Inst); Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Sanofi (Inst); Takeda
Research Funding - Pfizer (Inst)
 
Josiane Otto
No Relationships to Disclose
 
Nicolas Poté
No Relationships to Disclose
 
Alexandra Langlais
No Relationships to Disclose
 
Franck Morin
No Relationships to Disclose
 
Martine Antoine
No Relationships to Disclose
 
Virginie Westeel
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Ipsen
Speakers' Bureau - Amgen; Bristol-Myers Squibb/Pfizer; Lilly; MSD
Travel, Accommodations, Expenses - AstraZeneca; Bristol Myers Squibb; Roche; Sanofi
 
Anne-Claire Toffart
No Relationships to Disclose